Modelling & Simulation and applications to longitudinal data - Programme Agenda
Modelling and simulation in the pharmaceutical industry - reflections from a statistician's perspective - Carl-Fredrick Burman - Astrazeneca
Simplicity, Complexity and Modelling - Stephen Senn - CRP-Santé
The use of modelling and simulation in drug approval - A regulatory view - Norbert Benda - Bfarm
Simulation for Decision Making - MSToolkit for Go/No Go - Chris Campbell - Mango Solutions
A Longitudinal Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy - Benjamin Ribba - INRIA
Using M&S to develop a novel longitudinal Model-based approach for efficacy assessments, with an application to biosimilars in rheumatoid arthritis - Didier Renard - Novartis
Longitudinal analysis at Roche- a Biostatistics and an M&S Perspective - Ulrich Beyer - Cheikh Diack - Roche
REVIEW of Workshop